Imaging has a growing role in the evaluation of obesity-related disorders and the effects of weight loss, especially given the increasing use of glucagon-like peptide 1 agonists. New imaging biomarkers are emerging. Artificial intelligence applications for automated quantification of body composition underline future capabilities of whole-body MRI to comprehensively assess patients with obesity.
- Mickael Tordjman
- Zahi A. Fayad
- Bachir Taouli
